IL312776A - Sirp gamma antibodies and uses thereof - Google Patents

Sirp gamma antibodies and uses thereof

Info

Publication number
IL312776A
IL312776A IL312776A IL31277624A IL312776A IL 312776 A IL312776 A IL 312776A IL 312776 A IL312776 A IL 312776A IL 31277624 A IL31277624 A IL 31277624A IL 312776 A IL312776 A IL 312776A
Authority
IL
Israel
Prior art keywords
seq
amino acid
antibody
acid sequence
cell
Prior art date
Application number
IL312776A
Other languages
English (en)
Hebrew (he)
Inventor
Allen Guo Yang Cai
Sandip Panicker
Eileen Lingshu Rose
Adam David Rosenthal
Original Assignee
Electra Therapeutics Inc
Allen Guo Yang Cai
Sandip Panicker
Eileen Lingshu Rose
Adam David Rosenthal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electra Therapeutics Inc, Allen Guo Yang Cai, Sandip Panicker, Eileen Lingshu Rose, Adam David Rosenthal filed Critical Electra Therapeutics Inc
Publication of IL312776A publication Critical patent/IL312776A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL312776A 2021-11-10 2022-11-10 Sirp gamma antibodies and uses thereof IL312776A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163277966P 2021-11-10 2021-11-10
PCT/US2022/079668 WO2023086906A2 (en) 2021-11-10 2022-11-10 Sirp gamma antibodies and uses thereof

Publications (1)

Publication Number Publication Date
IL312776A true IL312776A (en) 2024-07-01

Family

ID=84488592

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312776A IL312776A (en) 2021-11-10 2022-11-10 Sirp gamma antibodies and uses thereof

Country Status (11)

Country Link
US (1) US20240400677A1 (https=)
EP (1) EP4429768A2 (https=)
JP (1) JP2024543385A (https=)
KR (1) KR20240099454A (https=)
CN (1) CN118591556A (https=)
AU (1) AU2022386652A1 (https=)
CA (1) CA3237787A1 (https=)
IL (1) IL312776A (https=)
MX (1) MX2024005740A (https=)
TW (1) TW202334224A (https=)
WO (1) WO2023086906A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Ｓｉｒｐアルファおよびｓｉｒｐベータ１抗体、ならびにそれらの使用
WO2025226685A1 (en) * 2024-04-22 2025-10-30 Electra Therapeutics, Inc. Sirp alpha, beta, gamma antibodies for treatment of epstein–barr virus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018118887A1 (en) * 2016-12-22 2018-06-28 Wake Forest University Health Sciences Sirp-gamma targeted agents for use in the treatment of cancer
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
JP7763666B2 (ja) * 2019-06-24 2025-11-04 アムジェン インコーポレイテッド 癌治療のためのＳＩＲＰγの阻害

Also Published As

Publication number Publication date
TW202334224A (zh) 2023-09-01
US20240400677A1 (en) 2024-12-05
KR20240099454A (ko) 2024-06-28
JP2024543385A (ja) 2024-11-21
CA3237787A1 (en) 2023-05-19
MX2024005740A (es) 2024-08-06
AU2022386652A1 (en) 2024-06-06
WO2023086906A3 (en) 2023-06-22
WO2023086906A2 (en) 2023-05-19
EP4429768A2 (en) 2024-09-18
CN118591556A (zh) 2024-09-03

Similar Documents

Publication Publication Date Title
CN109219618B (zh) 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
US20210047404A1 (en) Cd33 antibodies and use of same to treat cancer
US20240400677A1 (en) Sirp gamma antibodies and uses thereof
IL298024A (en) Antibodies to sirp alpha, sirp beta 1, and sirp gamma and their uses
IL295509A (en) Steap2 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Compounds That Bind Steap2 and CD3, and Their Uses
EA031025B1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
IL267567B2 (en) Anti-cd3 antibody for use in the treatment or prophylaxis of cancer, and molecules containing said antibody
KR20220129030A (ko) 항-Gal3 항체 및 사용 방법
US20240424128A1 (en) Humanized antibodies against nectin-2 and drug conjugates thereof
JP7350740B2 (ja) Ｉｌｄｒ２アンタゴニストおよびその組み合わせ
JP7843824B2 (ja) 抗体および使用方法
CA3207703A1 (en) Anti-s100a4 humanized antibodies, uses and methods
JP7812988B2 (ja) Ｌｅｗｉｓ Ｙに対するヒト化抗体
CN112552411A (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
JP2024513205A (ja) 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体およびその使用
JP2021501583A (ja) 抗体および使用方法
US20260055187A1 (en) Methods and compositions for treating autoimmune, allergic and inflammatory diseases
KR20210031913A (ko) 항-인간 pd-l1 항체 및 그것의 용도
KR20240055852A (ko) D3-결합 분자 및 이의 용도
KR20240021294A (ko) 항-her3 항체, 이를 함유하는 항체-약물 접합체 및 그 용도
US20250101008A1 (en) Heterobifunctional molecules for binding ccr2 and methods of treating medical conditions using same
KR20220053000A (ko) Cr2 결합 단백질 및 의료 요법에서의 그의 용도